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DYNAMICS OF RECOVERY IN DOUBLE UMBILICAL CORD BLOOD TRANS-
PLANTATIONWITH AN EX-VIVO MESENCHYMAL CELL EXPANDED UNIT:
FASTER RECOVERY WITH ENGRAFTMENT OF THE EXPANDED UNIT
Saliba, R.M.1, de Lima, M.1, McMannis, J.-, Robinson, S.1, Shpall, E.1,
Champlin, R.E.1, Bosque, D.M.1, Parmar, S.1, Rondon, G.1,
Simmons, P.2, Alousi, A.1 1The University of Texas MDAnderson Cancer
Center; 2The University of Texas Health Science Center, Houston
Double cord blood transplantation (CBT) with ex-vivo expansion
aims at overcoming the delayed engraftment frequently observed af-
ter CBT. Thirty-one patients received myeloablative therapy with
melphalan, fludarabine, thiotepa and ATG followed by double
CBT for treatment of hematologic malignancies. One of the 2 units
was expanded (exp) ex-vivo in a co-culture with either third party
haploidentical family member marrow derived mesecnchyal stem
cells (N5 8) or off-the-shelf mesenchymal progenitor cells fromAn-
gioblast (N 5 23). Both CB units were matched in at least 4/6 HLA
antigens with the patient, and contained a minimum of 1x107 TNC/
Kg per unit. The majority of patients (pts) received CBT for treat-
ment of acute leukemia including AML / MDS (64%) and ALL
(19%), and 42% were in remission at CBT.Median age was 36 years
(range 2.8-62). The non-exp unit was matched with the pt in 6/6
HLA antigens in 3%, 5/6 in 26% and 4/6 in 71% of cases; the cor-
responding distribution for the exp unit was 6%, 29%, 64%. En-
graftment was documented in 29 evaluable pts at a median of 15
(range 9 to 42) days for neutrophils and 40 (range 18 to 62) days
for platelets. Day 30 chimerism showed evidence of engraftment of
the non-exp unit only in 15 (52%) pts, and of both units in 13
(45%) pts, including 9 and 4 in whom the non-exp and the exp
unit dominated, respectively. Chimerism was undetermined in 1
pt. Comparison of the rate of recovery in pts who had (N 5 13)
and those who did not have (N 5 15) evidence of engraftment of
the exp unit showed that neutrophils and platelet recovery was faster
when the exp unit engrafted (median of 15 vs. 19 days for neutrophils;
and 38 vs. 40 days for platelet). This difference did not reach statis-
tical significance however. The median numbers of TNC and
CD34+ cells infused/Kg were significantly higher in the engrafted
exp than in the non-engrafted exp unit (p\0.05). Sixteen pts were di-
agnosed with grade II-IV aGVHD including 12 within 100 days post
CBT.GVHDwas severe (grade III-IV) in 5 pts.Onunivariate analysis,
there was a trend for a higher 6 month rate of grade II-IV aGVHD
when the exp unit engrafted (cumulative incidence (CI) 65% vs
49%, P 5 0.2); when the non-exp unit was only 4/6 HLA matched
with the pt (CI 65% vs 25%), p 5 0.2; and when CMV serostatus
was reactive in both the recipient and in the non-exp unit (CI 77%
vs 35%, p 5 0.1). The investigation of CB expansion is warranted in
a larger study population and accrual to our study continues.
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AN INSTITUTIONAL EXPERIENCE OF ADVERSE EFFECTS IN PATIENTS OF
ADVANCED AGE USING CYCLOSPORINE AND MYCOPHENOLATE
MOFETIL FOR GRAFT VERSUS HOST DISEASE PROPHYLAXIS IN REDUCED
INTENSITY CONDITIONED TRANSPLANT
Allen, B.E.1, Tyler, K.B.2 1Oregon Health and Science University, Port-
land, OR; 2Oregon Health and Science University, Portland, OR
Hematopoietic cell transplant in those with advanced age and/or
with a higher number of co-morbid factors is a viable treatment option
in this new era of reduced intensity conditioning (RIC) (McClune, et
al, 2010; JCO, 2010). Based on the intensity of conditioning, RIC
transplantation may require a greater degree of immune suppression
to decrease the risk of graft rejection. However, greater efficacy may
be counter balanced bymore toxicity, particularly in older patient pop-
ulations for whom these treatments are being developed. For fludara-
bine/TBI 200cGy conditioning with cyclosporine (CSA) and
mycophenolate mofetil (MMF) graft versus host disease (GvHD) pro-
phylaxis, CSAdosing is targeted at levels of 500-600ng/mL. In this set-
ting, 12% of patients (median age 54) undergoing RIC procedures
with these conditions experienced grade 3-5 nephrotoxicity, as defined
by the NCI CTC (Diaconescu, et al, Blood, 2004). These toxicities
may be even more highly accentuated in older patients. To better ap-
preciate the prevalence and severity of adverse effects related to CSA
exposure, we analyzed data from 91 patients over age 60 undergoing
RIC transplant at our institution from 2001 – 2010 who received
CSA/MMF GvHD prophylaxis.Our research found numerous CSA related adverse effects includ-
ing: electrolyte imbalances (100%) (hypomagnesia, hypokalemia and
hyperkalemia); nephrotoxicity (88%); neurotoxicity (12%) including
PRES and tremor; musculoskeletal effects in particular weakness
(11%); cardiovascular impacts from CSA induced hypertension
(53%) and hematologic toxicity from micro-angiopathic hemolytic
anemia (1%).
The above described toxicities associated with CSA are well-
known, yet in our review of this cohort of RIC transplants the inci-
dence of CSA related adverse events was pronounced. This level of
adverse events requires more aggressive monitoring and manage-
mentwhich leads to increased resource utilization ofmedical person-
nel and dollars, and may have a negative effect on patient outcomes.
In practice, we should continue to explore ways to optimize patient
care while controlling expense and resource utilization, and obtain
a greater understanding of the role that age and co-morbid factors
have on the transplant course given the expanding role of RIC. To
that end, we are currently comparing the rates of CSA-induced
complications in this cohort to a group of comparable patients un-
dergoing myeloablative transplant.
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L-LEUCYL-L-LEUCINE METHYL ESTER (LLME) TREATED NON-MYELOA-
BLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
(HSCT) FOR PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
Wagner, J.L., Grosso, D.A., Brunner, J., Carabasi, M.A., Filicko-
O’Hara, J.E., Mookerjee, B., Flomenberg, N. Thomas Jefferson
University, Philadelphia, PA
GVHDremains an obstacle for allogeneicHSCT.While T cell de-
pletion of donor grafts results in much lower incidences of GVHD,
rejection and poor immune recovery are often associated with this ap-
proach. To address these issues, we developed a transplant approach
using LLME to test the hypothesis that the selected depletion of T
cells containing cytotoxic effector granules would result in less signif-
icant GVHD while at the same time preserving GVT effects and in-
fectious immunity. LLME preferentially kills cytotoxic effector
granule bearing lymphocytes including most NK and CD8 T cells
with relative sparing of CD4T cells. Fourteen patients, with a median
age of 57 years with high risk disease were transplanted from related or
unrelated donors after a conditioning regimen of flu/cyclo/ara-C.
Prior to the infusion of the donor inoculum, we performed CD34 se-
lection using the Isolex system to separate the graft into CD34+ and
CD34- fractions. TheCD34- fractionwas then treatedwithLLME to
selectively deplete the cytotoxic effector granule containing subsets,
thus avoiding stem cell exposure to LLME. Patients received the
CD34 selected stem cell product (median CD34 dose 4.13 x 106/
kg). This HSC product contained 5 x 104 untreated CD3 cells/kg in
the initial 6 patients treated, but due to significant GVHD, the final
8 patients received 2.5 x 104 untreated CD3 cells/kg. One day later,
the LLME treated CD34- fraction (median CD3 dose 8.74 x106
/kg) was infused. One patient died shortly after the stem cell infusion
from infectious complications. All 13 evaluable patients engrafted
WBCby day 14.Two patients experienced late rejection.One of these
patients is still alive 3 years later with evidence of recurrent disease and
the other patient eventually died of relapsed disease. Of the remaining
11 patients, 3 patients developed grade III-IV GVHD and 1 patient
developed cGVHD. All 4 of these patients died of GVHD related
causes. Three patients died of complications from relapsed disease
and 1 additional patient died of infectious complications. Four pa-
tients are alive at a minimum of 3 years post transplant. Two of these
patients have relapsed disease, 1 patient is disease free with 100% do-
nor chimerism and one patient is disease free with a persistence of 5%
host cells. This study shows that LLME can be used to treat lympho-
cytes without affecting initial engraftment, but relapse and GVHD
remain significant barriers in this high risk population.
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MELPHALAN AND TOTAL-BODY IRRADIATION (MEL-TBI) IS AN EFFEC-
TIVE CONDITIONING REGIMEN FOR ALLOGENEIC STEM CELL TRANS-
PLANTATION (ALLO-SCT) IN PATIENTS WITH VERY POOR-RISK
REFRACTORY HEMATOLOGIC MALIGNANCIES
Akpek, G., Marangoz, D., Ilyas, C., Akbulut, V., Bhatnagar, B.,
Ruehle, K., Badros, A.Z., Yanovich, S., Rapoport, A.P. University of
Maryland Medical Center, Baltimore, MD
